Language Select
Varian Logo

Calypso® Soft Tissue Beacon® Transponder Receives FDA 510(k) Clearance

Varian’s Calypso® soft tissue Beacon® transponder, which helps enhance the precision of radiotherapy and radiosurgery procedures, has been cleared by the U.S. Food and Drug Administration (FDA) for implantation into soft tissue throughout the body, with the exception of the lung. The transponders emit a nonionizing electromagnetic signal that is monitored and tracked in real time by the Calypso GPS for the Body® tumor tracking technology, enabling intrafraction motion management for more precise tumor targeting. Clinicians can use the new Calypso transponders in most places where they would have used standard fiducial markers—such as gold seeds—to localize a tumor, with the added benefit of continuous position tracking throughout treatment delivery.

Get Centerline Delivered to Your Inbox.
Subscribe Now